Medicare Enrolled
Dr. Haris Zahoor, MD
Medical Oncology · Houston, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Zahoor from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Zahoor? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Zahoor
Dr. Haris Zahoor is a medical oncology in Houston, TX, with 16 years in practice. Based on federal Medicare data, Dr. Zahoor performed 112,003 Medicare services across 4,889 unique beneficiaries.
Between the years covered by Open Payments, Dr. Zahoor received a total of $12,007 from 28 pharmaceutical and/or device companies across 58 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Zahoor is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 16 years in practice▲ Top 7% volume in TX$ $12,007 industry payments
Medicare Practice Summary
Medicare Utilization ↗112,003
Medicare services
Top 7% in TX for medical oncology
4,889
Unique beneficiaries
$15
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~7,000 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) | 19,500 | $1 | $3 |
| Nivolumab injection (Opdivo) | 14,160 | $24 | $95 |
| Contrast dye for imaging (iodine-based) | 12,325 | $0 | $2 |
| Denosumab injection (Prolia/Xgeva) | 11,280 | $18 | $63 |
| Pembrolizumab injection (Keytruda) | 7,800 | $43 | $173 |
| Anti-nausea injection (fosaprepitant) | 7,650 | $0 | $3 |
| Daratumumab injection (Darzalex) | 5,940 | $38 | $201 |
| Paclitaxel chemotherapy injection | 5,597 | $0 | $1 |
| Epoetin alfa injection (Procrit) for anemia | 4,260 | $6 | $28 |
| Injection, eflapegrastim-xnst, 0.1 mg | 3,300 | $25 | $83 |
| Dexamethasone injection (steroid) | 2,641 | $0 | $1 |
| Injection, docetaxel, 1 mg | 2,232 | $1 | $11 |
| Injection, fosaprepitant (teva), not therapeutically equivalent to j1453, 1 mg | 1,800 | $0 | $3 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,690 | $1 | $21 |
| Complete blood count (CBC) with differential | 1,407 | $8 | $22 |
| Blood draw (venipuncture) | 1,169 | $8 | $9 |
| Comprehensive metabolic blood panel | 980 | $10 | $31 |
| Injection, granisetron hydrochloride, 100 mcg | 720 | $0 | $4 |
| Lactate dehydrogenase (enzyme) level | 681 | $6 | $21 |
| Flow cytometry, additional marker | 570 | $18 | $57 |
| Injection, leucovorin calcium, per 50 mg | 528 | $3 | $25 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 480 | $88 | $726 |
| Office visit, established patient (30-39 min) | 460 | $92 | $285 |
| Injection, fluorouracil, 500 mg | 397 | $2 | $16 |
| Injection of additional new drug or substance into vein | 374 | $11 | $43 |
| Administration of chemotherapy into vein, 1 hour or less | 329 | $94 | $362 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 321 | $21 | $82 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 317 | $3 | $23 |
| Drug injection, under skin or into muscle | 316 | $10 | $44 |
| Office visit, established patient, complex (40-54 min) | 298 | $132 | $376 |
| Injection, carboplatin, 50 mg | 261 | $2 | $17 |
| Office visit, established patient (20-29 min) | 254 | $60 | $201 |
| Magnesium level test | 182 | $7 | $19 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 130 | $47 | $184 |
| Physical therapy exercise, per 15 min | 118 | $16 | $79 |
| Ct scan of chest with contrast | 116 | $53 | $391 |
| Injection, diphenhydramine hcl, up to 50 mg | 96 | $1 | $3 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 95 | $25 | $86 |
| Administration of additional new drug or substance into vein, 1 hour or less | 87 | $47 | $175 |
| CT scan of abdomen and pelvis with contrast | 85 | $165 | $725 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 74 | $125 | $775 |
| Administration of chemotherapy into vein, each additional hour | 69 | $20 | $80 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 68 | $1,091 | $3,597 |
| Basic metabolic blood panel | 68 | $8 | $24 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 67 | $130 | $1,400 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 63 | $53 | $204 |
| Unclassified drugs | 51 | $1 | $3 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 46 | $1 | $6 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 45 | $15 | $57 |
| Urinalysis, manual | 42 | $3 | $10 |
| New patient office visit, complex (60-74 min) | 42 | $154 | $500 |
| Irrigation of implanted venous access drug delivery device | 41 | $18 | $68 |
| Application of on-body injector for under skin injection | 39 | $14 | $54 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 37 | $117 | $344 |
| Administration of additional new drug or substance into vein using push technique | 35 | $39 | $151 |
| Infusion into a vein for hydration, 31-60 minutes | 32 | $24 | $89 |
| Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free | 26 | $33 | $83 |
| Flu vaccine administration | 26 | $28 | $41 |
| Infusion, normal saline solution , 1000 cc | 26 | $2 | $8 |
| Flow cytometry technique for dna or cell analysis, first marker | 25 | $49 | $177 |
| New patient office visit (45-59 min) | 25 | $106 | $385 |
| Phosphate level test | 23 | $5 | $14 |
| Injection of drug or substance into vein | 22 | $26 | $102 |
| Red blood count, manual test | 19 | $4 | $12 |
| CT scan of chest, without contrast | 17 | $32 | $312 |
| Nuclear medicine study whole body with ct scan | 16 | $1,064 | $3,609 |
| Red blood count, automated test | 13 | $4 | $11 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
17.9% high complexity
76.0% medium
6.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$12,007
Total received (2018-2024)
Avg $1,715/year across 7 years
Top 35% in TX for medical oncology
28
Companies
58
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$5,800 (48.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$5,345 (44.5%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$862 (7.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$177
2023$213
2022$188
2021$86
2020$810
2019$4,424
2018$6,109
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Bayer HealthCare Pharmaceuticals Inc.
$5,800
Exelixis Inc.
$5,084
Amgen Inc.
$216
Janssen Scientific Affairs, LLC
$110
EMD Serono, Inc.
$77
E.R. Squibb & Sons, L.L.C.
$68
Celgene Corporation
$67
PFIZER INC.
$63
Eisai Inc.
$62
Seagen Inc.
$44
Daiichi Sankyo Inc.
$41
AVEO Pharmaceuticals, Inc.
$40
TerSera Therapeutics LLC
$36
Incyte Corporation
$33
Epizyme, Inc.,
$32
Gilead Sciences, Inc.
$32
G1 Therapeutics, Inc.
$24
ARRAY BIOPHARMA INC
$21
Aveo Pharmaceuticals, Inc.
$20
ABBVIE INC.
$19
Merck Sharp & Dohme LLC
$18
JAZZ PHARMACEUTICALS INC.
$17
Novartis Pharmaceuticals Corporation
$16
Pharmacyclics LLC, an AbbVie Company
$16
CTI BioPharma Corp.
$14
Novocure Inc.
$13
Dendreon Pharmaceuticals LLC
$13
Blueprint Medicines Corporation
$13
Top 3 companies account for 92.4% of total payments
Associated products mentioned in payments ›
ADCETRIS · AYVAKIT · BAVENCIO · Bavencio · COSELA · Cabometyx · Enhertu · Erleada · FOTIVDA · IBRANCE · IMBRUVICA · JAKAFI · Lenvima · MEKINIST · OPDIVO · OPZELURA · Optune · PROVENGE · Pomalyst · REBLOZYL · TAZVERIK · TUKYSA · Tepmetko · Trodelvy · VENCLEXTA · Vectibix · Vonjo · WELIREG · XALKORI · Xermelo · Xofigo · ZEPZELCA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (48%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Equivalent to $11 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
183
Per 100K population
3.8
County median income
$73,104
Nearest hospital
WOMANS HOSPITAL OF TEXAS,THE
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Zahoor is a mixed practice specialist, with above-average Medicare volume (top 7% in TX), and consulting-driven industry engagement, with 16 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Zahoor experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Zahoor performed 19,500 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Zahoor receive payments from pharmaceutical companies?
Yes. Dr. Zahoor received a total of $12,007 from 28 companies across 58 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Zahoor's costs compare to other medical oncologys in Houston?
Dr. Zahoor's average Medicare payment per service is $15. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Zahoor) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in Houston
Browse medical oncologys in Houston ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in TX
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in TX
Which TX medical oncologys receive the most from drug and device companies.
By company
Bayer HealthCare Pharmaceuticals Inc. Payments to Doctors
See all physicians who received payments from Bayer HealthCare Pharmaceuticals Inc..
By company
Exelixis Inc. Payments to Doctors
See all physicians who received payments from Exelixis Inc..
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology